Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prosena Therapeutics

- PMLiVE

GSK halts bid for Votrient maintenance use

Pulls European application for indication in advanced ovarian cancer

- PMLiVE

GSK invests in African research and manufacturing

Boosts R&D for non-communicable diseases

- PMLiVE

EMA clears GSK’s diabetes therapy Eperzan

Once-weekly GLP-1 therapy will line-up against Victoza and Byetta

- PMLiVE

GSK withdraws melanoma combo in EU

EMA says it needs more data to review Mekinist and Tafinlar

- PMLiVE

GSK’s cancer vaccine flunks another trial

MAGE-A3 fails to improve survival in lung cancer patients

- PMLiVE

GSK to hire doctors as product champions

Will use in-house personnel instead of external speakers to present information

- PMLiVE

GSK set to file severe asthma candidate by year-end

Mepolizumab reduces frequency of exacerbations in late-stage trial

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

GSK raises stake in Indian subsidiary

Company eyes long-term growth of market

- PMLiVE

Death of a salesman

Will people communicate the same way if their results are not being measured?

- PMLiVE

Five companies breach ABPI code

Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA

- PMLiVE

GSK files Promacta for anaemia indication in US

FDA will review drug under ‘breakthrough’ designation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links